vs
Affirm Holdings, Inc.（AFRM）とANI PHARMACEUTICALS INC（ANIP）の財務データ比較。上の社名をクリックして会社を切り替えられます
Affirm Holdings, Inc.の直近四半期売上が大きい（$401.4M vs $247.1M、ANI PHARMACEUTICALS INCの約1.6倍）。Affirm Holdings, Inc.の純利益率が高く（32.3% vs 11.1%、差は21.2%）。Affirm Holdings, Inc.の前年同期比売上増加率が高い（32.5% vs 29.6%）。Affirm Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$118.0M vs $29.1M）。過去8四半期でAffirm Holdings, Inc.の売上複合成長率が高い（43.5% vs 34.1%）
アファーム・ホールディングスは米国の金融テクノロジー企業で、購入時ローンや後払い決済サービス（BNPL）を提供しています。PayPal共同創業者のマックス・レフチンが2012年に設立した米国最大のBNPL事業者で、2025年現在利用者数は約2600万人、年間決済処理額は370億米ドルに上ります。
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
AFRM vs ANIP — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $401.4M | $247.1M |
| 純利益 | $129.6M | $27.5M |
| 粗利率 | — | — |
| 営業利益率 | 29.3% | 14.1% |
| 純利益率 | 32.3% | 11.1% |
| 売上前年比 | 32.5% | 29.6% |
| 純利益前年比 | 61.3% | 367.5% |
| EPS（希薄化後） | $0.37 | $1.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $401.4M | $247.1M | ||
| Q3 25 | $320.5M | $227.8M | ||
| Q2 25 | $306.6M | $211.4M | ||
| Q1 25 | $272.5M | $197.1M | ||
| Q4 24 | $303.0M | $190.6M | ||
| Q3 24 | $231.8M | $148.3M | ||
| Q2 24 | $224.0M | $138.0M | ||
| Q1 24 | $195.0M | $137.4M |
| Q4 25 | $129.6M | $27.5M | ||
| Q3 25 | $80.7M | $26.6M | ||
| Q2 25 | $69.2M | $8.5M | ||
| Q1 25 | $2.8M | $15.7M | ||
| Q4 24 | $80.4M | $-10.3M | ||
| Q3 24 | $-100.2M | $-24.2M | ||
| Q2 24 | $-45.1M | $-2.3M | ||
| Q1 24 | $-133.9M | $18.2M |
| Q4 25 | 29.3% | 14.1% | ||
| Q3 25 | 19.9% | 15.9% | ||
| Q2 25 | 18.9% | 6.6% | ||
| Q1 25 | -3.1% | 13.3% | ||
| Q4 24 | -1.4% | -2.3% | ||
| Q3 24 | -57.2% | -13.8% | ||
| Q2 24 | -32.8% | 3.7% | ||
| Q1 24 | -82.5% | 14.8% |
| Q4 25 | 32.3% | 11.1% | ||
| Q3 25 | 25.2% | 11.7% | ||
| Q2 25 | 22.6% | 4.0% | ||
| Q1 25 | 1.0% | 8.0% | ||
| Q4 24 | 26.5% | -5.4% | ||
| Q3 24 | -43.2% | -16.3% | ||
| Q2 24 | -20.2% | -1.7% | ||
| Q1 24 | -68.7% | 13.2% |
| Q4 25 | $0.37 | $1.14 | ||
| Q3 25 | $0.23 | $1.13 | ||
| Q2 25 | $0.22 | $0.36 | ||
| Q1 25 | $0.01 | $0.69 | ||
| Q4 24 | $0.23 | $-0.45 | ||
| Q3 24 | $-0.31 | $-1.27 | ||
| Q2 24 | $-0.13 | $-0.14 | ||
| Q1 24 | $-0.43 | $0.82 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.5B | $285.6M |
| 総負債低いほど良い | $9.0B | — |
| 株主資本純資産 | $3.5B | $540.7M |
| 総資産 | $13.0B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 2.54× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.5B | $285.6M | ||
| Q3 25 | $1.4B | $262.6M | ||
| Q2 25 | $1.4B | $217.8M | ||
| Q1 25 | $1.4B | $149.8M | ||
| Q4 24 | $1.2B | $144.9M | ||
| Q3 24 | $1.0B | $145.0M | ||
| Q2 24 | $1.0B | $240.1M | ||
| Q1 24 | $1.3B | $228.6M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.3B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.5B | $540.7M | ||
| Q3 25 | $3.3B | $505.8M | ||
| Q2 25 | $3.1B | $436.8M | ||
| Q1 25 | $2.9B | $418.6M | ||
| Q4 24 | $2.8B | $403.7M | ||
| Q3 24 | $2.8B | $405.9M | ||
| Q2 24 | $2.7B | $455.8M | ||
| Q1 24 | $2.6B | $452.0M |
| Q4 25 | $13.0B | $1.4B | ||
| Q3 25 | $11.5B | $1.4B | ||
| Q2 25 | $11.2B | $1.3B | ||
| Q1 25 | $10.4B | $1.3B | ||
| Q4 24 | $10.5B | $1.3B | ||
| Q3 24 | $10.1B | $1.3B | ||
| Q2 24 | $9.5B | $920.8M | ||
| Q1 24 | $9.2B | $914.5M |
| Q4 25 | 2.54× | — | ||
| Q3 25 | 2.35× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 2.49× | — | ||
| Q4 24 | 2.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.67× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $173.7M | $30.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $118.0M | $29.1M |
| FCFマージンFCF / 売上 | 29.4% | 11.8% |
| 設備投資強度設備投資 / 売上 | 13.9% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 1.34× | 1.10× |
| 直近12ヶ月FCF直近4四半期 | $619.1M | $171.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $173.7M | $30.4M | ||
| Q3 25 | $374.6M | $44.1M | ||
| Q2 25 | $74.6M | $75.8M | ||
| Q1 25 | $210.4M | $35.0M | ||
| Q4 24 | $312.0M | $15.9M | ||
| Q3 24 | $196.9M | $12.5M | ||
| Q2 24 | $68.8M | $17.4M | ||
| Q1 24 | $208.2M | $18.3M |
| Q4 25 | $118.0M | $29.1M | ||
| Q3 25 | $320.2M | $38.0M | ||
| Q2 25 | $23.5M | $71.8M | ||
| Q1 25 | $157.4M | $32.5M | ||
| Q4 24 | $268.1M | $13.5M | ||
| Q3 24 | $152.7M | $7.7M | ||
| Q2 24 | $30.5M | $13.0M | ||
| Q1 24 | $161.7M | $13.7M |
| Q4 25 | 29.4% | 11.8% | ||
| Q3 25 | 99.9% | 16.7% | ||
| Q2 25 | 7.7% | 34.0% | ||
| Q1 25 | 57.7% | 16.5% | ||
| Q4 24 | 88.5% | 7.1% | ||
| Q3 24 | 65.9% | 5.2% | ||
| Q2 24 | 13.6% | 9.4% | ||
| Q1 24 | 82.9% | 10.0% |
| Q4 25 | 13.9% | 0.5% | ||
| Q3 25 | 17.0% | 2.7% | ||
| Q2 25 | 16.7% | 1.9% | ||
| Q1 25 | 19.5% | 1.3% | ||
| Q4 24 | 14.5% | 1.3% | ||
| Q3 24 | 19.0% | 3.2% | ||
| Q2 24 | 17.1% | 3.2% | ||
| Q1 24 | 23.8% | 3.3% |
| Q4 25 | 1.34× | 1.10× | ||
| Q3 25 | 4.64× | 1.66× | ||
| Q2 25 | 1.08× | 8.87× | ||
| Q1 25 | 75.03× | 2.23× | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.00× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AFRM
| Merchant Network | $328.4M | 82% |
| Virtual Card Network | $73.0M | 18% |
| Commercial Agreement Amazon | $1.9M | 0% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
